Neuroblastoma is the most common extracerebral solid malignancy in young children. This tumor is characterized by extreme clinical and progressive variability, ranging from spontaneous regression without treatment to rapidly fatal progression. Neuroblastomas can be divided into 3 entities: neonatal tumors, whose prognosis is very favorable, localized tumors whose treatment is essentially surgical after possible tumor reduction chemotherapy; finally, metastatic tumors, in particular in the bone marrow and the skeleton, the survival rate of which has stagnated at 30%.